SCSeemant Chaturvedi

Seemant Chaturvedi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Seemant Chaturvedi has a total of 906 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • David G. Sherman Lecture: The Eternal Quest for Optimal Stroke Prevention

    by Seemant Chaturvedi

    Despite decades of clinical trial activity in stroke prevention, critical gaps remain in the evidence base guiding management of symptomatic carotid and intracranial stenosis and the quality of anticoagulation care delivered to patients with atrial fibrillation (AF). This article synthesizes recent evidence and ongoing research efforts addressing 2 enduring challenges: demonstrating the value of intensive medical therapy relative to interventional approaches and improving the quality of stroke prevention care in AF. Previous trials focused on intracranial stenosis established that aggressive, protocol-driven medical management substantially reduces recurrent vascular events. In the realm of carotid stenosis, landmark trials conducted >3 decades ago no longer reflect modern pharmacological capabilities. Emerging evidence from plaque imaging, particularly intraplaque hemorrhage on magnetic resonance imaging, suggests that stenosis severity alone is an insufficient determinant of treatment strategy. Simultaneously, strokes related to AF continue to rise in the United States, driven by demographic aging, and large vessel occlusion strokes attributable to undertreated AF represent a preventable burden on the health system. Patient-centered, precision stroke prevention requires contemporary prospective data, integration of advanced vascular imaging biomarkers, and systematic improvements in preventative therapies for patients with AF. Targeting these areas holds promise for improving stroke prevention in the coming decades.

  • Nonoperative management of patients with symptomatic carotid stenosis

    by Matthew Yen, Larry B. Goldstein, Brian Silver, Seemant Chaturvedi

  • Open Access

    Colchicine for Prevention of Recurrent Stroke—Are we CONVINCED?

    by Gian Marco De Marchis, Tolga Dittrich, Prachi Mehndiratta, Seemant Chaturvedi

  • Kapil Sethi, MD (1953–2024)

    by Seemant Chaturvedi, Pradeep Sahota

  • Trends in the Utilization of Different Carotid Revascularization Modalities in the United States Over a 17-Year Period

    by Fadar O. Otite, Nicholas A. Morris, Ahmed Sabra, Smit D. Patel, Nnabuchi Anikpezie, Anurag Sahoo, David Landzberg, Claribel D. Wee, Amit Singla, Julius Gene Silva Latorre, et al.

    In October 2023, the Centers for Medicare & Medicaid Services (CMS) in the United States expanded coverage for carotid artery stenting (CAS) to include non-high-risk patients with carotid disease. The aim of this study was to provide a 17-year snapshot of trends in carotid revascularization practices in the United States before this CMS policy change went into effect. We conducted a serial cross-sectional study using the 2006-2022 National Inpatient Sample and a retrospective cohort study using the State Emergency and Inpatient Databases of Florida (2005-2021), Georgia (2010-2020), Maryland (2012-2021), and New York (2005-2020). Cases of carotid revascularizations in these databases were identified using International Classification of Diseases codes. We calculated age-specific and sex-specific proportions of revascularizations for CAS and combined annual CAS/carotid endarterectomy (CEA) counts with census data to determine utilization rates per 100,000 population. Joinpoint regression estimated annualized percentage change (APC) over time. Hospitalizations in the 6 months preceding revascularization defined symptomatic vs asymptomatic cases and characterized the subset with symptomatic stenosis. Of 1,779,948 weighted revascularizations, the mean patient age was 71.0 years and 40.9% were performed in women. 17.2% of procedures were CAS, and this proportion more than doubled from 14.3% to 29.0%. Transcarotid artery revascularization accounted for 9.1% in 2022. The CAS proportion increased across age groups, including in those aged older than 70 years and in women, even after excluding mechanical thrombectomy admission. Carotid revascularization usage per 100,000 population declined (APC -3.9%, 95% CI -4.1% to -3.3%) but plateaued after 2015. Although CEA utilization declined from 2006 to 2022 (APC -5.5%, 95% CI -5.9% to -5.1%), CAS use declined from 2006 to 2016 (APC -3.2%, 95% CI -4.6% to -2.1%) but increased from 2016 to 2022 (APC 12.0%, 95% CI 10.1%-14.1%). Only 25.7% of revascularizations in the 4 states were performed for symptomatic disease, with 75.3% of hospitalizations in women for asymptomatic disease. Despite uncertain benefit in selected age and sex groups, including those older than 70 years and with asymptomatic carotid disease, CAS use increased across groups over the past decade and now accounts for >25% of carotid revascularizations in the United States.


  • Comparative Rates of Acute Ischemic Stroke Incidence

    by Fadar O. Otite, Nicholas A. Morris, Nnabuchi Anikpezie, Danielle Pitter, Ronald Miller, Abdulaziz T. Bako, Ehimen Aneni, Kunakorn Atchaneeyasakul, Smit D. Patel, Anurag Sahoo, et al.

    There are limited data on the incidence of acute ischemic stroke (AIS) among Native Hawaiian or Pacific Islander (NHOPI) individuals in the United States and on how their incidence compares with that of other racial and ethnic groups. We compared age and sex-specific incidence of AIS in NHOPI individuals with those of non-Hispanic White (NHW), non-Hispanic Black (NHB), Hispanic and Asian individuals residing in 4 states of the United States over the past decade. Using a retrospective approach, we examined the State Ambulatory Surgery, Emergency, and Inpatient Databases of Florida (2005-2020), Georgia (2010-2020), Maryland (2012-2020), and New York (2005-2020). Based on available data, we applied a 6-year look-back period for Florida and New York and a 3-year look back period for Georgia and Maryland. Incident AIS cases among adults (≥18 years) were identified using International Classification of Diseases codes. Cases were combined with census data to compute incidence. Random-effects Poisson regression models were used to compare incidence between various race and ethnicity groups. We identified 799,150 incident cases of AIS among residents of all 4 states. The median age of these cases was 70.0 years, and 50.1% were female individuals. The age and sex-standardized incidence of AIS in NHOPI was 591.4 (95% CI 559.3-623.5), whereas that in NHW individuals was 179.7 (95% CI 179.2-180.3). After multivariable adjustment, the incidence in NHOPI was >3 times that of NHW individuals (adjusted incidence rate ratio [aIRR] 3.30, 95% CI 1.70-6.42). Incidence was also higher in NHOPI compared with Hispanic (aIRR 3.91, 95% CI 2.13-7.19) and Asian individuals (aIRR 5.66, 95% CI 3.27-9.80), whereas the NHOPI incidence in comparison with that of NHB individuals showed a trend toward significance (aIRR 1.94, 95% CI 0.99-3.77, p = 0.052). After further stratification by age, the incidence gap between NHOPI and NHW individuals was present in most age groups but was most marked in adults age ≥80 years (aIRR 4.24, 95% CI 2.46-7.33). Over the period 2011-2020, incidence of AIS among NHOPI individuals residing in Florida, Georgia, Maryland, and New York was higher than among individuals from other major race and ethnicity groups. Additional studies are needed to see whether the findings in these 4 states are occurring nationally.


  • Shrinking Role for Carotid Revascularization in Stroke Prevention

    by Colin P. Derdeyn, Seemant Chaturvedi, Bruce A. Wasserman

    The surgical or endovascular treatment of patients with asymptomatic atherosclerotic carotid artery stenosis has become controversial, given the advances in medical treatment since the original pivotal trials establishing efficacy for surgical endarterectomy. The ECST-2 (European Carotid Stenosis Trial-2) recently reported no benefit of revascularization procedures over modern medical treatment alone. In addition, its findings extend to lower-risk symptomatic patients. These data add a brick to the wall supporting medical management alone for these 2 patient populations. Future work should focus on identifying patients most likely to benefit from revascularization—shifting from traditional anatomic criteria such as percent diameter stenosis to patient-specific risk factors, including physiological and hemodynamic information.


  • Outcome Prediction After Thrombectomy

    by James Ernest Siegler, Seemant Chaturvedi


  • Open Access

    An International, Expert-based, Multispecialty Delphi Consensus Document on Stroke Risk Stratification and the Optimal Management of Patients with Asymptomatic and Symptomatic Carotid Stenosis

    by Kosmas I. Paraskevas, Ali F. AbuRahma, Wesley S. Moore, Peter Gloviczki, Bruce A. Perler, Daniel G. Clair, Christopher J. White, Carlo Setacci, Eric A. Secemsky, Peter A. Schneider, et al.

    Background: The optimal management of patients with asymptomatic (AsxCS) and symptomatic (SxCS) carotid stenosis is controversial and includes intensive medical management (i.e., best medical therapy [BMT]) with/without an additional carotid revascularization procedure (i.e., carotid endarterectomy [CEA], transfemoral carotid artery stenting [TFCAS] or TransCarotid Artery Revascularization [TCAR]). The aim of this international, expert-based, multispecialty Delphi Consensus document was to reconcile the conflicting views regarding the optimal management of AsxCS and SxCS patients. Methods: A three-round Delphi Consensus process was performed including 63 experts from Europe (n=37) and the United States (n=26). A total of 6 different clinical scenarios were identified involving patients with either AsxCS or SxCS. For each scenario, 5 treatment options were available: (i) BMT alone, (ii) BMT plus CEA, (iii) BMT plus TFCAS, (iv) BMT plus TCAR, or (v) BMT plus CEA/TFCAS/TCAR. Consensus was achieved when >70% of the Delphi Consensus participants agreed on a therapeutic approach. Results: Most participants concurred that BMT alone is not adequate for the management of a 70-year-old fit male or female patient with 80-99% AsxCS (52/63; 82.5% and 45/63; 71.5%, respectively). In contrast, most panelists would opt for BMT alone for an 80-year-old male AsxCS patient with several co-morbidities (48/63; 76.2%). The majority of participants would opt for BMT plus a carotid revascularization procedure for an 80-year-old male SxCS patient with a recent ipsilateral cerebrovascular event, an ipsilateral 70-99% SxCS and a 5-year predicted risk of ipsilateral ischemic event of 10% (54/63; 85.7%), 15% (59/63; 93.6%), or 20% (63/63; 100%). The opinion of U.S.-based participants varied from that of Europe-based respondents in some scenarios. Conclusions: The present Delphi Consensus document showed that a “one-size-fits-all” approach is not appropriate for patients with either AsxCS or SxCS. Patients should be stratified according to their future stroke risk and should be treated accordingly.

  • Percutaneous Endoscopic Gastrostomy Usage in Acute Ischemic Stroke

    by Fadar Oliver Otite, Yash Nene, Ahmed Sabra, Lee Pfaff, Nnabuchi Anikpezie, Emmanuel Oladele Akano, Smit D. Patel, Devin J. Burke, Claribel D. Wee, Julius Gene Silva Latorre, et al.

    Data on how percutaneous endoscopic gastrostomy (PEG) utilization has changed over time in patients with acute ischemic stroke (AIS) in the United States are sparse. This study evaluates 17-year trends in PEG utilization in AIS hospitalizations in the United States. The 2006-2022 National Inpatient Sample was used to conduct a serial cross-sectional study. International Classification of Diseases codes were used to identify primary AIS hospitalizations with and without PEG. We used joinpoint regression to compute the annualized percentage change (APC) in PEG usage over time and used multivariable regression to evaluate the association of IV thrombolysis (IV-tPA), mechanical thrombectomy (MT), and other hospitalization factors with odds of PEG use. Of 8,079,538 primary AIS admissions over the study period, the overall PEG prevalence was 3.9% but usage in the subset of AIS admissions undergoing MT was 11.0%. PEG utilization increased with age in both sexes (18-39-year-olds: men 2.7%; women 2.5%; 80 years or older: men 4.7% and women 4.6%). After multivariable adjustment, increasing Elixhauser comorbidity scores (OR 1.31, 95% CI 1.30-1.32) and MT utilization (OR 1.61, 95% CI 1.54-1.68) were associated with higher odds of PEG use while IV-tPA was associated with lower odds of utilization (OR 0.94, 95% CI 0.91-0.97) when compared with no treatment. PEG use declined by 2.9% annually across the study period (average APC 2.9%, 95% CI -3.2 to -2.5%), but the rate of decline was fastest in the period 2014-2018 (APC -7.4%, 95% CI -8.6 to -4.9), followed by 2006-2014 (APC -1.9%, 95% CI -2.5 to -0.9). Utilization did not change significantly in the period 2018-2022. The average time from admission to PEG placement was 9.3 days, and this increased progressively over time (p trend <0.001). PEG use in patients with AIS declined over the past decade. This decline is likely due to multifactorial reasons that warrant further studies, but changing clinical practice toward allowing for some more time for patients with AIS to recover from poststroke dysphagia may be one of the potential contributory factors.